
Innate Pharma S.A. IPHA
€ 1.61
0.54%
Innate Pharma S.A. Langfristige Verbindlichkeiten | IPHA
Langfristige Verbindlichkeiten Jährlich Innate Pharma S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.8 M | 69.2 M | 83.6 M | 104 M | - | 105 M | - | 87.2 M | 95.2 M | 119 M | 174 M | 5.29 M | 6.32 M | 9.57 M | 18 M |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 174 M | 5.29 M | 71 M |
Langfristige Verbindlichkeiten Vierteljährlich Innate Pharma S.A.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 47.8 M | 58.4 M | 69.2 M | 84.5 M | 83.6 M | 104 M | - | - | - | - | 80.2 M | - | 90 M | - | 106 M | - | - | - | 62.1 M | - | - | - | 87.2 M | - | - | - | 95.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in EUR-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 106 M | 47.8 M | 80.6 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AbbVie
ABBV
|
81.7 B | $ 263.04 | 0.49 % | $ 465 B | ||
|
AbCellera Biologics
ABCL
|
326 M | $ 11.41 | 2.15 % | $ 3.41 B | ||
|
Фармсинтез
LIFE
|
13.2 M | - | - | - | ||
|
Aclaris Therapeutics
ACRS
|
5.95 M | $ 5.53 | 6.02 % | $ 678 M | ||
|
ADC Therapeutics SA
ADCT
|
341 M | $ 1.09 | 3.74 % | $ 139 M | ||
|
Amryt Pharma plc
AMYT
|
302 M | - | - | $ 621 M | ||
|
Evelo Biosciences
EVLO
|
40.3 M | - | -14.46 % | $ 27.9 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | ||
|
Chimerix
CMRX
|
196 K | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | ||
|
ADMA Biologics
ADMA
|
99.5 M | $ 8.61 | 0.16 % | $ 2.05 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
31.9 M | - | -9.21 % | $ 2.55 M | ||
|
89bio
ETNB
|
23.1 M | - | - | $ 1.55 B | ||
|
Fusion Pharmaceuticals
FUSN
|
4.31 M | - | - | $ 1.41 B | ||
|
Guardion Health Sciences
GHSI
|
272 K | - | -0.31 % | $ 3.64 M | ||
|
Genocea Biosciences
GNCA
|
64.5 M | - | -15.0 % | $ 3.04 M | ||
|
Gritstone Oncology
GRTS
|
30.5 M | - | 0.42 % | $ 213 M | ||
|
G1 Therapeutics
GTHX
|
9.54 M | - | - | $ 370 M | ||
|
Harpoon Therapeutics
HARP
|
59.9 M | - | - | $ 763 M | ||
|
Humanigen
HGEN
|
2.34 M | - | -81.12 % | $ 4.28 M | ||
|
HOOKIPA Pharma
HOOK
|
6.68 M | - | -6.92 % | $ 79.4 M | ||
|
Intercept Pharmaceuticals
ICPT
|
541 M | - | - | $ 643 M | ||
|
IGM Biosciences
IGMS
|
12.2 M | - | - | $ 76.9 M | ||
|
IMV
IMV
|
8.95 M | - | - | $ 13.1 M | ||
|
Intra-Cellular Therapies
ITCI
|
20 M | - | - | $ 13.6 B | ||
|
Kinnate Biopharma
KNTE
|
93.1 M | - | - | $ 123 M | ||
|
Chinook Therapeutics
KDNY
|
940 K | - | - | $ 2.6 B | ||
|
Kaleido Biosciences
KLDO
|
22.2 M | - | -3.69 % | $ 12.4 M | ||
|
Kronos Bio
KRON
|
33.6 M | - | 1.49 % | $ 50.8 M | ||
|
Karuna Therapeutics
KRTX
|
150 K | - | - | $ 12.2 B | ||
|
Landos Biopharma
LABP
|
73 M | - | 0.58 % | $ 144 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
148 M | - | - | $ 154 M | ||
|
LogicBio Therapeutics
LOGC
|
13.1 M | - | - | $ 229 M | ||
|
Lumos Pharma
LUMO
|
6 M | - | - | $ 35.3 M | ||
|
Merrimack Pharmaceuticals
MACK
|
14.9 M | - | - | $ 216 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
25.2 M | - | - | $ 23.9 M | ||
|
Mirati Therapeutics
MRTX
|
999 K | - | - | $ 3.3 B | ||
|
NexImmune
NEXI
|
4.94 K | - | 70.13 % | $ 4.12 M | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
752 K | - | -37.48 % | $ 476 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
368 K | - | -19.68 % | $ 18.4 M | ||
|
ObsEva SA
OBSV
|
35.4 M | - | -15.52 % | $ 10.5 M | ||
|
Oncorus
ONCR
|
41.6 M | - | -8.54 % | $ 3.19 M | ||
|
OncoSec Medical Incorporated
ONCS
|
6.35 M | - | 31.87 % | $ 1.61 M | ||
|
Oncternal Therapeutics
ONCT
|
91 K | - | -24.12 % | $ 1.56 M | ||
|
Opiant Pharmaceuticals
OPNT
|
18.7 M | - | - | $ 109 M | ||
|
Orchard Therapeutics plc
ORTX
|
50.9 M | - | 1.02 % | $ 90.8 M |